Platelets play an important role in hemostasis and their function traits are emerging to have important genetic influences. Platelet function is complex: with vascular injury, normal platelets adhere to exposed collagen and to von Willebrand factor bound to collagen. [1] [2] [3] This triggers the generation and secretion of thromboxane A 2 (TXA 2 ) and platelet storage granule release. [1] [2] [3] Platelets then undergo further activation, with intracellular signaling triggered by their released TXA 2 , adenosine diphosphate (ADP), serotonin, and other agonists (such as thrombin) that are generated at the sites of vessel injury. [1] [2] [3] Genetic defects can impair platelet hemostatic function in many ways, from modifying platelet-vessel wall interactions, through changes in the number of circulating platelets, and/or their size, adhesive properties, responses to agonists, intracellular signaling, granule release, and the feedback that signaling and secretion have on platelet activation and prohemostatic function.
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The purpose of this review is to summarize the current state of knowledge on the genetic loci that influence platelet functions and traits, including the genes that may contain disease-causing mutations in those characterized forms of inherited platelet disorders and other conditions that modify platelets. ). [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Although there are uncertainties about the degree to which these loci predict normal or pathological platelet variability, the heritability of platelet traits, including platelet "reactivity" to agonists in function tests, offers an attractive explanation for the significant correlation of platelet responses to different agonists in clinical aggregation and secretion assays, for individuals with and without bleeding problems.
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Among the heritable markers associated with platelet traits, some show associations with size, count, and/or function, and some are associated with more than one platelet trait. Some associations do not clearly map to a single gene and/or show an association to multiple loci (see ►Table 1). Some single nucleotide polymorphisms (SNPs) have been associated with a platelet characteristic in multiple populations, consistent with an influence upon different genetic backgrounds [14] [15] [16] 18, 35 (see ►Table 1). Meta-analyses, which increase the power for detecting associations, have found additional associations for platelet traits (►Table 2 summarizes data for associations with p values 1 Â 10 À5 ).
GWAS have associated some noncoding regions of the genome with platelet traits, which indirectly suggests that transcriptional or posttranscriptional regulatory mechanisms are involved in regulating platelet function. 36 Given that both platelets and megakaryocytes contain unique regulatory microRNA (miRNA), 29 some GWAS have explored if the genes encoding these short RNA sequences are associated with platelet function traits. 16 Although strong associations of platelet traits with genes encoding miRNA have not been established by GWAS, this possibility needs to be tested with larger numbers of subjects. At present, there is small but important overlap between genetic loci that are mutated in platelet disorders (►Table 3) and those that are known to influence platelet traits (►Tables 1 and 2). Among the genes that show associations to platelet traits by GWAS (►Tables 1 and 2) Genetic Loci Associated with Platelet Traits and Disorders Bunimov et al. 295
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This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. association, there is a need to validate the GWAS data by other experimental models, to verify that the candidate genes influence platelet traits, as has been done for supervillin. 28 Once characterized, candidate genes that are verified to influence platelet traits will provide attractive targets for investigations of the causes of unidentified bleeding disorders. At present, the knowledge on associations has not reached the point where genotyping can be used to predict an individual's platelet "reactivity" in function tests. It is also important to recognize that GWAS provides information on the genetic causes of variability, but this technique is unlikely to identify rare causes of variability and it will not identify the genes or miRNA with important roles in platelet function if the genetic sequence has little or no variability between subjects.
Gene Defects in Characterized Hereditary Disorders of Platelet Numbers and/or Function
There has been significant progress in finding the molecular defect of inherited platelet disorders, particularly for rare disorders, including those associated with syndromic features, as summarized in ►Table 3 and illustrated in ►Fig. 1.
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Nonetheless, only a few of the genes identified to contain mutations in persons with inherited defects of platelet function overlap the genes that show a significant association to platelet "reactivity" in other subjects (►Tables 1-3) . Such an overlap is evident in the platelet disorders that are associated with mutations in the genes encoding glycoprotein (GP) VI, 61, 62 33, 67, 68 There are many potential candidate genes for uncharacterized, inherited platelet disorders, given the many genes transcribed by megakaryocytes and the large number of proteins found in platelets. 6, [8] [9] [10] [11] [69] [70] [71] [72] [73] [74] Genetic mutations resulting in characterized inherited platelet disorders have been identified to alter various aspects of platelets, including their circulating numbers and hemostatic function (►Fig. 1). Perhaps not surprisingly, most of the mutations are in the genes that have well-known, and important roles in regulating platelet numbers and/or function. 59, 60 Some are associated with thrombocytopenias, with or without changes to platelet shape and volume. 75, 76 As a comprehensive review of the diagnosis and management of all characterized inherited platelet disorders is beyond the scope of this review, readers interested in information on specific disorders are encouraged to read the references cited for different conditions. Mechanistically, the characterized defects are difficult to classify into disorders of number or function as some affect both. The defects involve proteins found in several different compartments within platelets, such as the following: (1) and HOXA11 93 (see ►Fig. 1 and ►Table 3). Additionally, some disorders are caused by mutations in the genes that affect the biogenesis of α-granules [94] [95] [96] [97] and dense granules. [98] [99] [100] [101] A unique copy number variation mutation, causing overexpression of the α-granule protein urokinase-type plasminogen activator by megakaryocytes in Quebec platelet disorder, leads to plasmin-mediated degradation of other stored α-granule proteins and a gain-of-function defect in clot lysis.
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The disorders that alter platelet surface receptors can impair platelet function in adhesion or aggregation, alter platelet interactions with collagen, von Willebrand factor, or other ligands (►Fig. 1 and ►Table 3), or alter the process of platelet activation by ADP, collagen or TXA2, and agonistinduced signaling (►Fig. 1 and ►Table 3). Recently, a mutation of the transmembrane protein16F, a Ca 2þ -activated chloride channel, was identified as the cause of the defective, agonist-induced scrambling of phospholipids and impaired membrane activation and procoagulant function of Scott syndrome. Platelet signaling, which is important for activation induced by agonists and platelet interactions with adhesive ligands, is impaired by mutations in genes encoding G proteins [105] [106] [107] and in proteins that regulate G-protein signaling. 108 Inside-out integrin activation is impaired by mutation in the gene for kindlin-3, an intracellular protein that interacts with β integrins. 
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Most patients with uncharacterized inherited platelet function disorders have "secretion defects" (also called "release" or "activation" defects) that impair platelet function in aggregation and/or dense granule release assays, often with multiple (but not necessarily all) agonists. 33, 34, 67, 68, [124] [125] [126] A comprehensive study of the genetic causes of inherited platelet secretion defects has never been undertaken. Inherited secretion defects include δ-granule deficiency, which can result from characterized, autosomal recessive, syndromic disorders associated with hypopigmentation (e.g., HermanskyÀPudlak syndrome, ChédiakÀHigashi syndrome, and Griscelli syndrome) 97 Genetic Loci Associated with Platelet Traits and Disorders Bunimov et al. 301
and variability in the general population, including platelet function. 13 GWAS, and meta-analyses of GWAS data, have provided new information on the genes that influence platelet function and traits (refer to ►Tables 1 and 2). Nonetheless, some caution is advised as many of the associated genes have not been tested for influence on platelet traits using other models (e.g., mouse knockouts 28 and zebrafish morpholinos 131 ) to validate their importance to platelet function and other platelet traits. It is likely that platelet function is influenced by many factors, including genetic background, ethnicity, gender and environment, and exposures to drugs that inhibit platelet function. Although the characterization of several disorders with an altered platelet phenotype has provided important new insights on the genes that influence platelet traits, the causes of most inherited platelet "secretion defects" still need to be thoughtfully characterized. Technical advances in molecular analysis of gene linkage and genomic sequences (e.g., full genome and exome sequencing) will facilitate the discovery of the disease-causing mutations of inherited platelet function disorders and increase our understanding of the genetic loci that influence platelet physiology and pathology.
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